HCP5 and breast carcinoma: A lower histocompatibility leukocyte antigen complex P5 (HCP5) expression level was ascertained in cisplatin-resistant breast cancer cells, while overexpressed HCP5 weakened cisplatin resistance in vivo and in vitro by upregulating PTEN [58].